Seven Fleet Capital Management LP Purchases New Holdings in MBX Biosciences, Inc. $MBX

Seven Fleet Capital Management LP purchased a new position in shares of MBX Biosciences, Inc. (NASDAQ:MBX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 18,200 shares of the company’s stock, valued at approximately $574,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. grew its holdings in shares of MBX Biosciences by 4,131.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,481 shares of the company’s stock worth $26,000 after purchasing an additional 1,446 shares in the last quarter. FNY Investment Advisers LLC acquired a new position in MBX Biosciences during the 3rd quarter worth approximately $27,000. GF Fund Management CO. LTD. acquired a new position in shares of MBX Biosciences during the fourth quarter worth $28,000. Royal Bank of Canada increased its holdings in MBX Biosciences by 59.6% in the 4th quarter. Royal Bank of Canada now owns 1,532 shares of the company’s stock worth $49,000 after purchasing an additional 572 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in MBX Biosciences by 117.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,896 shares of the company’s stock valued at $51,000 after buying an additional 1,567 shares during the last quarter.

MBX Biosciences Price Performance

Shares of NASDAQ MBX opened at $43.03 on Friday. The company has a 50-day moving average price of $33.22 and a 200-day moving average price of $33.20. The stock has a market capitalization of $2.05 billion, a P/E ratio of -19.47 and a beta of 0.75. MBX Biosciences, Inc. has a 1 year low of $9.43 and a 1 year high of $45.85.

Analyst Ratings Changes

A number of brokerages have recently commented on MBX. TD Cowen reiterated a “buy” rating on shares of MBX Biosciences in a report on Thursday, March 12th. Lifesci Capital upgraded MBX Biosciences to a “strong-buy” rating in a report on Tuesday, March 31st. Stifel Nicolaus set a $56.00 target price on MBX Biosciences in a research report on Tuesday, May 12th. UBS Group reaffirmed a “buy” rating on shares of MBX Biosciences in a report on Tuesday, February 24th. Finally, Truist Financial upped their price target on MBX Biosciences from $50.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $60.22.

About MBX Biosciences

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.